Tracker Globale delle Epidemie

In generale no. La maggior parte delle specie di hantavirus — incluse Sin Nombre, Puumala, Hantaan e Seoul — si trasmette solo per contatto con roditori infetti o con i loro escrementi, urina e saliva. L'unica eccezione documentata è il virus Andes (ANDV), presente soprattutto in Argentina e Cile. Per il virus Andes è stata registrata una trasmissione interumana limitata, ma solo in casi di contatto stretto e prolungato (per esempio conviventi o operatori sanitari senza protezioni). Il cluster della MV Hondius riguarda il virus Andes, ed è per questo che è in corso un tracciamento dei contatti a livello internazionale nonostante la rarità del contagio interumano.

Ebola virus disease has a historical case-fatality rate of 25-90% depending on strain, with Bundibugyo ebolavirus — the strain driving the active 2026 outbreak in the Democratic Republic of the Congo and Uganda — historically around 25-40%. Per the WHO Situation Report of 18 May 2026, the outbreak had recorded 528 reported cases (2 lab-confirmed in Uganda, 526 under investigation) and 132 deaths, with 668 contacts identified. No vaccine or monoclonal antibody therapy is currently approved for the Bundibugyo strain, unlike Zaire ebolavirus which has Ervebo and two approved antibody treatments. WHO declared the outbreak a Public Health Emergency of International Concern on 18 May 2026.

The first symptoms of Ebola virus disease appear 2-21 days after exposure (typically 8-10 days) and include abrupt high fever (≥38.6°C/101.5°F), intense headache, severe muscle pain, extreme fatigue, sore throat, and loss of appetite. By days 3-7 a gastrointestinal phase follows, with profuse watery diarrhoea (up to 10 L/day in severe cases), vomiting, abdominal pain, and hiccups. In roughly half of severe cases, a haemorrhagic phase develops around days 5-10 — bleeding from injection sites and mucosal surfaces, and a non-itchy rash on the trunk by day 5-7. A person is not contagious until symptoms begin.

The MV Hondius 2026 cluster is the first documented hantavirus outbreak linked to cruise ship travel, but the ship environment was not itself the source of transmission. Hantavirus does not spread easily from person to person — the source was an index case who had spent four months in Andes virus-endemic areas of Argentina, Chile, and Uruguay before boarding. Andes virus is the only hantavirus strain with documented (but limited) person-to-person transmission, requiring prolonged close contact. WHO and ECDC assessed the risk to the general public from the MV Hondius cluster as 'low' to 'very low'. The episode demonstrates that travelers returning from Andes-endemic South American regions within 8 weeks of symptoms should disclose that travel history to clinicians immediately.

Hantavirus is diagnosed using a combination of laboratory tests and clinical criteria. The gold standard for Hantavirus Pulmonary Syndrome (HPS) is serology: IgM and IgG ELISA antibody tests that become positive within days of symptom onset. RT-PCR (reverse-transcription polymerase chain reaction) can detect viral RNA in blood during the early febrile phase before antibodies develop, and was used to confirm Andes virus in the MV Hondius cluster cases. Supportive CBC findings include thrombocytopenia (platelets often below 150,000/µL), immunoblasts (activated lymphocytes), hemoconcentration (rising hematocrit), and left-shifted neutrophilia. Chest X-ray and CT show bilateral interstitial infiltrates as HPS progresses to pulmonary edema. Diagnosis typically combines a compatible clinical picture, recent rodent exposure or travel to an endemic area, and confirmatory serology or PCR. Standard influenza or COVID-19 tests will NOT detect hantavirus — physicians must order specific hantavirus serology panels, available through most state and national reference laboratories in the US, EU, Argentina, and Chile.